1 / 41

MENOPAUSE

MENOPAUSE. PHYSIOLOGY OF MENSTRUATION. The female has a fixed number of gamets for her reproductive life. 7 million oogonia at 20 weeks’ gestatation 700 000 at the time of birth 400 000 by puberty 100 000 by 30 – 35 years of age. PHYSIOLOGY OF MENSTRUATION AND MENOPAUSE.

isleen
Download Presentation

MENOPAUSE

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. MENOPAUSE

  2. PHYSIOLOGY OF MENSTRUATION The female has a fixed number of gamets for her reproductive life. • 7 million oogonia at 20 weeks’ gestatation • 700 000 at the time of birth • 400 000 by puberty • 100 000 by 30 – 35 years of age

  3. PHYSIOLOGY OF MENSTRUATION AND MENOPAUSE Relative changes in FSH as a Function of Life Stages

  4. PHYSIOLOGY OF MENSTRUATION AND MENOPAUSE • A women ovulates approximately 400 oocytes during her reproductive years. • During the reproductive cycle, a cohort of oocytes is stimulated to begin maturation, but only 1 or 2 complete the process and are ovulated. • Menopause occurs when the residual follicles are refractory to elevated concentration of FSH.

  5. PERIMENOPAUSE The period of 5 to 10 years before the menopause. Symptoms: • Increasingly inefficient reproductive functions • Increasing of the FSH level • Decreases the frequency of ovulation

  6. PHYSIOLOGY OF MENSTRUATION AND MENOPAUSE Steroid Hormone Serum Concentrations

  7. MENOPAUSE The permanent cessation of menses The mean age of women at menopause is 51 years Approximately 4% of women undergo a natural menopause befor 40 year of age – „premature ovarian failure”.

  8. MENOPAUSE „Menopause is a physiologic process, however, the consequences of ovarian failure can diminish a woman’s quality of life and can predispose her to osteoporosis and increased risk of cardiovascular disease.”

  9. PHYSIOLOGY OF MENSTRUATION AND MENOPAUSE The postmenopausal ovary produces testosterone and androstendione primarily from stromal and hilar cells

  10. PHYSIOLOGY OF MENSTRUATION AND MENOPAUSE The major source of postmenopausal estrogens is adrenal androgens, particulary androstendione, which undergoes aromatization by peripherial tissues to estrone.

  11. MENOPAUSE CATEGORIES OF SYMPTOMS: • Vasomotor disturbances: hot flushes, night sweats, palpitations headaches, muscle aches • Organ atrophy: - vaginal dryness, atrophy, dyspareunia - urinary incontinence, dysuria, infections - brest atrophy - skin dryness and thinning, brittle nails

  12. MENOPAUSE CATEGORIES OF SYMPTOMS: • Changes in mood and libido: anxiety, insomnia, depression, irritability, inability to concentrate, lack of energy • Accelerated bone mineral loss leading to osteoporosis (long term) • Coronary artery disease (long term)

  13. HORMONAL REPLACEMENT THERAPY The indication for HRT: • the treatment of climacteric symptoms • prevention of postmenopausal diseases with individually tailored approach based also on an individual risk-benefit score

  14. NATURAL 17-oestradiol Oestradiol valerate Oestrone piperazine sulphat Conjugated equine oestrogens Oestriol SYNTHETIC Ethinyloestradiol Mestranol Diethylstilboestrol Dienoestrol HORMONAL REPLACEMENT THERAPYTypes of oestrogens

  15. HORMONAL REPLACEMENT THERAPYRoutes of estrogens administration • Oral • Transdermal • Intranasal • Transbucal • Transvaginal • Intravenous • Intramuscular

  16. HORMONAL REPLACEMENT THERAPYEstrogens administration modes • Long-term high doses administartion • Pulsatile administartion

  17. HORMONAL REPLACEMENT THERAPYMechanism of estrogen action • Two different intracellular estrogen receptor proteins: ER and ER • Different expression of ER and ER in different target tissues and in different stages of developement • Different binding affinity between the two receptors for 17-estradiol, androgen metabolites, phytoestrogens and estrogen agonist/antagonist

  18. New possibilities in HRT Different distribution of ER receptors in the different target organs enabled to had developed the group of selective estrogen receptor modulators (SERM) (Raloxifen)

  19. HORMONAL REPLACEMENT THERAPYEstrogens The natural estrogens produce fewer metabolic side effects than synthetic Synthetic estrogens with a steroid structure (i.e. ethinyl estradiol) are most frequenty used in oral contarception Conjugated equine estrogens –in use mostly in USA Native human estrogens (i.e. 17-estradiol) or estradiol valerate – mostly in use in Europe

  20. RISK FACTORS OF ATHEROSCLEROSIS AND CIRCULATORY SYSTEM DISEASES AND THE RESPONSE TO THE ESTROGEN REPLACEMENT THERAPY PostmenopauseEstrogen supplementationphysiologyOral TTS Arterial resistance Uterine artery Carotid artery

  21. Estrogen influence on serum lipid level according to routs of administration • Postmenopause • OralTTS • Total cholesterol • HDL   • LDL  • VLDL • Triglyceride 0/ physiology

  22. RISK FACTORS OF ATHEROSCLEROSIS AND CIRCULATORY SYSTEM DISEASES AND THE RESPONSE TO THE ESTROGEN REPLACEMENT THERAPY PostmenopauseEstrogene supplementationphysiologyOralTTS HDL2   Ch-LDL  Triglyceride Renine substrates0/ Blood preassure0/0/ Insulin basal level0/ Prostacycline 0/ Procoagulant factors VII & X0/

  23. ESTROGEN INFLUENCE ON CARBOHYDRATE METABOLISM • Transdermal E2 administration decreases the basal • insulin level and increases insulin clearanse, when administrated orally does not influence insulin turnover • E2 decreases insulin resistance, conjugated E interacts equivocally • E2 is necessary, among others, to support pancreatic insulin secretion

  24. ESTROGEN REPLACEMENT BENEFITS IN BONES „Estrogen therapy given for at least 5 years early in the climacteric period reduces subsequent hip and Colles fracture by 50% and vertebral fractures by up to 90%.” Consensus Development Conference, Copenhagen, 1990

  25. RISK FACTORS FOR OSTEOPOROSIS MAJOR: Low bone density High rate of bone loss OTHER: Genetic Environmental Lifestyle Hormonal factors Other diseases

  26. RISK FACTORS FOR OSTEOPOROSIS GENETIC: • European or Asian race • Slender build • Previous osteoporotic fracture • Family history of osteoporosis ENVIRONMENTAL: • Low exposure to sunlight

  27. RISK FACTORS FOR OSTEOPOROSIS LIFESTYLE: • Low dietary calcium intake • Smoking • Chronic alcohol consumption • Sedentary lifestyle HORMONAL FACTORS: • Early menopause • Nulliparity

  28. RISK FACTORS FOR OSTEOPOROSIS OTHER DISEASES: Liver disorders Thyrotoxicosis Hyperparathyroidism Chronic debilitating illness Prolonged immobility Oral corticosteroid therapy Postgastrectomy malabsorption states

  29. 19-Nortestosterone Derivatives Norethisteron acetate Norethisteron Levonorgestrel Desogestrel Gestodene Lynestrol Ethynodiol diacetate Norgestimat 17-Hydroxyprogesterone Derivatives Medroxyprogesterone acetate Dydrogesterone Megestrol acetate Cyptoterone acetate Medrogestone HORMONAL REPLACEMENT THERAPYTypes of progestogens

  30. HORMONAL REPLACEMENT THERAPYProgestogens • All progestogens are able to induce secretory phase in the estrogen-primed endometrium • Depending on their derivation they may have androgenic and/or estrogenic effects or antiandrogenic and/or antiestrogenic effects

  31. HORMONAL REPLACEMENT THERAPYBiological activity of progestogens

  32. HORMONAL REPLACEMENT THERAPYProgestogens • According to their chemical structure, progestogens have different effects on lipid and carbohydrate metabolism • Progestogens may induce some adverse metabolic effects to estrogens

  33. HORMONAL REPLACEMENT THERAPY Adverse effects of HRT (thromboembolism, coronary artery disease, brest and endometrial cancer) are higly related to the drugs, dosage, regimen or route of administration used, and to duration of use

  34. CONTRAINDICATIONS TO HRT • Pregnancy • Lactation • Severe disturbances of liver functions • Jaundice or persistent itching during previous pregnancy • Previous or existing liver tumours • Estrogendepended tumors of uterus, ovaries or brest or suspicion of such tumours

  35. CONTRAINDICATIONS TO HRT • Endometriosis • Existing or previous thromboembolic processes • Severe diabetes mellitus with vascular changes • Sickle-cell anaemia • Disturbances of lipo-metabolism

  36. CONTRAINDICATIONS TO HRT • A history of herpes of pregnancy • Otosclerosis with deterioration during pregnancy

  37. REASONS FOR IMMEDIATE DISCONTINUATION OF HRT • Occurrence for the first time of migrainous headaches • More frequent occurrence of unusually severe headaches • Sudden perceptual disorders (vision or hearing) • First signs of thrombophlebitis or thromboembolic symptoms

  38. REASONS FOR IMMEDIATE DISCONTINUATION OF HRT • Pain and tightness in chest • Impending operation (six weeks beforhand) • Immobilization • Onset of jaundice • Onset of hepatitis • Generalized pruritis

  39. REASONS FOR IMMEDIATE DISCONTINUATION OF HRT • Increase in epileptic seizures • Significant rise in blood pressure • Pregnancy

  40. What to do when, because of contraindications, the patient is not suitable for HRT? • Taking nutritional advice to ensure balanced diet with adequate calcium intake • Stopping smoking, and limiting alcohol consumption • Exercising regularly to help maintain helthy bones • Learning yoga or relaxation techniques to help cope with hot flushes, anxiety or irritability

More Related